series-a
Stage
2023
Founded
1
Investors
About
Antag Therapeutics is a biopharmaceutical company focused on developing treatments for obesity and related metabolic disorders through GIP receptor antagonism. Its lead candidate, AT7687, is a first-in-class peptide-based therapy designed to block biological pathways contributing to fat storage and insulin resistance.
Explore Antag Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.